| Sean Donahue, MD, PHD | |
|
3601 Tvc, Nashville, TN 37232-0001 | |
| (615) 322-3000 | |
| Not Available |
| Full Name | Sean Donahue |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 35 Years |
| Location | 3601 Tvc, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083706402 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD26701 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
The WHO on Wednesday released its World Health Statistics 2012 report, which "for the first time includes a look at blood pressure and glucose levels, two of the risk factors for diabetes and cardiovascular disease," according to the Associated Press/Washington Post.
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
Psychological distress has long been associated with negative health outcomes for cancer patients, though specific reasons remain unclear.
An international research group led by the Centenary Institute has developed a world first genetic risk score (GRS) test able to identify patients at high-risk of developing alcohol-related cirrhosis.
› Verified 1 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
The WHO on Wednesday released its World Health Statistics 2012 report, which "for the first time includes a look at blood pressure and glucose levels, two of the risk factors for diabetes and cardiovascular disease," according to the Associated Press/Washington Post.
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
Psychological distress has long been associated with negative health outcomes for cancer patients, though specific reasons remain unclear.
An international research group led by the Centenary Institute has developed a world first genetic risk score (GRS) test able to identify patients at high-risk of developing alcohol-related cirrhosis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean Donahue, MD, PHD 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: (615) 322-3000 | Sean Donahue, MD, PHD 3601 Tvc, Nashville, TN 37232-0001 Ph: (615) 322-3000 |
News Archive
The WHO on Wednesday released its World Health Statistics 2012 report, which "for the first time includes a look at blood pressure and glucose levels, two of the risk factors for diabetes and cardiovascular disease," according to the Associated Press/Washington Post.
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
Psychological distress has long been associated with negative health outcomes for cancer patients, though specific reasons remain unclear.
An international research group led by the Centenary Institute has developed a world first genetic risk score (GRS) test able to identify patients at high-risk of developing alcohol-related cirrhosis.
› Verified 1 days ago
Dr. Peter L Sonkin, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 23rd Ave N, Suite 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 | |
Dr. Edward Chaum, MD PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-936-3000 | |
Dr. Mark R Melson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4306 Harding Pike, Suite 106, Nashville, TN 37205 Phone: 615-297-5798 Fax: 615-383-6646 | |
Dr. Everton L. Arrindell, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 - 23rd Avenue North, Suite 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 | |
Dr. Christine Shieh, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Lucas Lee Groves, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Brigid K Marshall, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 23rd Ave N Ste 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 |